Credit Suisse’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $22.8M | Buy |
176,136
+8,399
| +5% | +$1.03M | 0.02% | 600 |
|
|
2023
Q4 | $16.2M | Buy |
167,737
+27,838
| +20% | +$2.67M | 0.02% | 723 |
|
|
2023
Q3 | $17M | Sell |
139,899
-84,932
| -38% | -$9.6M | 0.02% | 687 |
|
|
2023
Q2 | $25.7M | Buy |
224,831
+31,659
| +16% | +$4.08M | 0.03% | 590 |
|
|
2023
Q1 | $26.6M | Sell |
193,172
-82,507
| -30% | -$10.7M | 0.03% | 586 |
|
|
2022
Q4 | $35.7M | Sell |
275,679
-11,552
| -4% | -$1.34M | 0.04% | 494 |
|
|
2022
Q3 | $31.8M | Sell |
287,231
-120,209
| -30% | -$12.1M | 0.04% | 519 |
|
|
2022
Q2 | $30.5M | Sell |
407,440
-190,722
| -32% | -$14M | 0.03% | 549 |
|
|
2022
Q1 | $46.7M | Sell |
598,162
-233,036
| -28% | -$17.8M | 0.04% | 464 |
|
|
2021
Q4 | $74.8M | Sell |
831,198
-4,927
| -0.6% | -$421K | 0.04% | 474 |
|
|
2021
Q3 | $77.3M | Buy |
836,125
+199,721
| +31% | +$15.4M | 0.04% | 460 |
|
|
2021
Q2 | $49.5M | Buy |
636,404
+30,554
| +5% | +$2.32M | 0.03% | 692 |
|
|
2021
Q1 | $45.2M | Buy |
605,850
+132,009
| +28% | +$12.2M | 0.02% | 754 |
|
|
2020
Q4 | $80.8M | Buy |
473,841
+69,756
| +17% | +$10.3M | 0.04% | 497 |
|
|
2020
Q3 | $56.7M | Buy |
404,085
+1,736
| +0.4% | +$264K | 0.03% | 559 |
|
|
2020
Q2 | $64.5M | Buy |
402,349
+8,157
| +2% | +$1.11M | 0.05% | 434 |
|
|
2020
Q1 | $38.6M | Sell |
394,192
-21,979
| -5% | -$2.51M | 0.03% | 527 |
|
|
2019
Q4 | $53.7M | Buy |
416,171
+75,541
| +22% | +$7.62M | 0.04% | 511 |
|
|
2019
Q3 | $25.7M | Buy |
340,630
+66,697
| +24% | +$7.88M | 0.02% | 771 |
|
|
2019
Q2 | $41.6M | Buy |
273,933
+31,581
| +13% | +$3.84M | 0.04% | 532 |
|
|
2019
Q1 | $28.9M | Buy |
242,352
+15,963
| +7% | +$2.05M | 0.03% | 661 |
|
|
2018
Q4 | $24.7M | Sell |
226,389
-8,548
| -4% | -$1.07M | 0.03% | 686 |
|
|
2018
Q3 | $37.9M | Buy |
234,937
+42,681
| +22% | +$5.83M | 0.03% | 535 |
|
|
2018
Q2 | $25.4M | Sell |
192,256
-192,475
| -50% | -$18.2M | 0.02% | 709 |
|
|
2018
Q1 | $28.5M | Buy |
384,731
+164,778
| +75% | +$11M | 0.03% | 670 |
|
|
2017
Q4 | $12.2M | Buy |
219,953
+133,001
| +153% | +$7.05M | 0.01% | 1140 |
|
|
2017
Q3 | $3.94M | Sell |
86,952
-3,307
| -4% | -$132K | ﹤0.01% | 1958 |
|
|
2017
Q2 | $3.04M | Sell |
90,259
-96,036
| -52% | -$3.13M | ﹤0.01% | 1947 |
|
|
2017
Q1 | $5.51M | Buy |
186,295
+112,899
| +154% | +$3.49M | 0.01% | 1590 |
|
|
2016
Q4 | $2.01M | Sell |
73,396
-4,116
| -5% | -$165K | ﹤0.01% | 2436 |
|
|
2016
Q3 | $4.76M | Buy |
77,512
+14,686
| +23% | +$444K | ﹤0.01% | 1698 |
|
|
2016
Q2 | $1.2M | Sell |
62,826
-389,984
| -86% | -$7.22M | ﹤0.01% | 2777 |
|
|
2016
Q1 | $8.84M | Buy |
452,810
+377,537
| +502% | +$6.6M | 0.01% | 1177 |
|
|
2015
Q4 | $2.9M | Sell |
75,273
-28,691
| -28% | -$930K | ﹤0.01% | 2018 |
|
|
2015
Q3 | $3.34M | Sell |
103,964
-36,900
| -26% | -$1.25M | ﹤0.01% | 1876 |
|
|
2015
Q2 | $4.29M | Buy |
140,864
+34,916
| +33% | +$714K | ﹤0.01% | 1877 |
|
|
2015
Q1 | $1.41M | Sell |
105,948
-43,799
| -29% | -$584K | ﹤0.01% | 2703 |
|
|
2014
Q4 | $2.17M | Buy |
149,747
+40,840
| +37% | +$692K | ﹤0.01% | 2474 |
|
|
2014
Q3 | $2.3M | Buy |
108,907
+30,602
| +39% | +$691K | ﹤0.01% | 2379 |
|
|
2014
Q2 | $2.33M | Buy |
78,305
+14,779
| +23% | +$467K | ﹤0.01% | 2590 |
|
|
2014
Q1 | $1.53M | Sell |
63,526
-72,750
| -53% | -$1.85M | ﹤0.01% | 2742 |
|
|
2013
Q4 | $2.78M | Buy |
136,276
+72,919
| +115% | +$2.17M | ﹤0.01% | 2369 |
|
|
2013
Q3 | $2.99M | Buy |
63,357
+12,053
| +23% | +$464K | ﹤0.01% | 2062 |
|
|
2013
Q2 | $1.95M | Buy |
+51,304
| New | +$1.83M | ﹤0.01% | 2291 |
|
Other funds holding SRPT
ACA
FCM
Credit Suisse's SRPT Position: Q1 2024 in Review
Credit Suisse increased its Sarepta Therapeutics (SRPT) stake by 5% in Q1 2024, buying an estimated $1.03M and bringing the position to 176,136 shares worth $22.8M. The position accounts for 0.02% of the portfolio, ranked #600.
Credit Suisse first reported a position in SRPT in Q2 2013 and has held it in 44 quarters since. The position peaked at $80.8M in Q4 2020. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.
- Credit Suisse held 176,136 shares of Sarepta Therapeutics worth $22.8M as of Q1 2024.
- Credit Suisse bought 8,399 Sarepta Therapeutics shares in Q1 2024, an estimated $1.03M.
- Sarepta Therapeutics made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #600 holding.
- Credit Suisse first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Sarepta Therapeutics position peaked at $80.8M in Q4 2020.
- 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.